News & Updates

Patients with inflammatory bowel disease (IBD) who have completed a COVID-19 vaccine regimen have a low risk of developing COVID-19, though receipt of mRNA vaccines may offer better protection, according to a small study presented at the Crohn’s and Colitis Congress 2022.

Patients requiring haemodialysis show higher infection rates of the coronavirus disease 2019 (COVID-19) as well as associated mortality rates, a new study has found.

Delays in endoscopies due to the coronavirus disease 2019 (COVID-19) pandemic does not seem to worsen clinical outcomes in patients with inflammatory bowel diseases (IBD), though healthcare utilization patterns appear to be affected, according to a study reported at the recently concluded 2022 Crohn’s & Colitis Congress (CCC 2022).

Persons living with HIV (PLWH) often switch from first-line antiretroviral therapies (ART) of non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PI) to second-line integrase strand transfer inhibitors (INSTI), a recent Japan study has found. PLWHs tend to stay on INSTIs for a long time thereafter.

The risk of cervical cancer and grade 3 cervical intraepithelial neoplasia (CIN3) was substantially reduced among girls who were offered the bivalent human papillomavirus (HPV) vaccine, particularly those who were offered it at age 12–13 years, according to an observational study from England.

Patients with inflammatory bowel disease (IBD) report that the COVID-19 pandemic is a “major concern” for them, reveals a study, noting that the cumulative prevalence is low in this cohort. At-risk patients must be identified and counseled individually.

The Pfizer-BNT162b2 vaccine for the coronavirus disease 2019 (COVID-19) effectively reduces the risk of serious outcomes and hospitalization in patients with inflammatory bowel diseases (IBD), though with slight variance in effectivity with respect to ongoing medications, reports a Qatar study presented at the recently concluded 2022 Crohn’s & Colitis Congress (CCC 2022).

Most patients with community-acquired pneumonia go untested for influenza even during flu season, which is unfortunate since a positive test result facilitates antiviral therapy, and early treatment leads to lower mortality, according to a study.